Search research articles
Contact Us
Filters
Showing results (21-30 of 40) with videos related to
Page
of 4
Sort By:
Journal for Immunotherapy of Cancer
|
September 7, 2019
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
Marijo Bilusic, Christopher R Heery, Julie M Collins, et al.
JAMA Network Open
|
February 27, 2020
Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Ananta Subedi, Sandra G Williams, Lawrence Yao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 5, 2018
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
Julius Strauss, Christopher R Heery, Jeffrey Schlom, et al.
The Oncologist
|
February 17, 2021
Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma
Peter Joseph DeMaria, Marijo Bilusic, Deric M Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 23, 2018
First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors
Julius Strauss, Christopher R Heery, Joseph W Kim, et al.
Journal for Immunotherapy of Cancer
|
March 25, 2021
Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)
Marijo Bilusic, Sheri McMahon, Ravi A Madan, et al.
The Oncologist
|
December 27, 2019
Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors
Julie M Collins, Renee N Donahue, Yo-Ting Tsai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 22, 2019
A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules
Margaret E Gatti-Mays, Julius Strauss, Renee N Donahue, et al.
Journal for Immunotherapy of Cancer
|
May 26, 2023
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma
Julius Strauss, Jean-Laurent Deville, Mario Sznol, et al.
The Oncologist
|
October 10, 2019
A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer
Margaret E Gatti-Mays, Jason M Redman, Renee N Donahue, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 40) with videos related to
Sort By:
Page
of 4
Journal for Immunotherapy of Cancer
|
September 7, 2019
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
Marijo Bilusic, Christopher R Heery, Julie M Collins, et al.
JAMA Network Open
|
February 27, 2020
Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Ananta Subedi, Sandra G Williams, Lawrence Yao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 5, 2018
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
Julius Strauss, Christopher R Heery, Jeffrey Schlom, et al.
The Oncologist
|
February 17, 2021
Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma
Peter Joseph DeMaria, Marijo Bilusic, Deric M Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 23, 2018
First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors
Julius Strauss, Christopher R Heery, Joseph W Kim, et al.
Journal for Immunotherapy of Cancer
|
March 25, 2021
Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)
Marijo Bilusic, Sheri McMahon, Ravi A Madan, et al.
The Oncologist
|
December 27, 2019
Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors
Julie M Collins, Renee N Donahue, Yo-Ting Tsai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 22, 2019
A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules
Margaret E Gatti-Mays, Julius Strauss, Renee N Donahue, et al.
Journal for Immunotherapy of Cancer
|
May 26, 2023
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma
Julius Strauss, Jean-Laurent Deville, Mario Sznol, et al.
The Oncologist
|
October 10, 2019
A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer
Margaret E Gatti-Mays, Jason M Redman, Renee N Donahue, et al.
Page
of 4